摘要
目的观察致敏的树突状细胞(DC)治疗卵巢癌时肿瘤标志物CA125的动态变化.评价树突状细胞的临床疗效和毒副作用。方法 20例不能耐受化疗的晚期卵巢癌患者随机分为树突状细胞治疗组(观察组)和单纯对症支持治疗组(对照组),治疗组分离患者外周血单核细胞,体外培养成致敏的树突状细胞,1周后回输,对照组给予对症支持治疗,治疗前后检测外周血中的CA125,并观察卡氏评分和毒副作用等临床指标。结果两组患者治疗前血清中的CA125和卡氏评分没有明显差别;治疗组生物治疗后CA125降低,卡氏评分升高,均有统计学意义;对照组治疗后CA125无明显变化,且卡氏评分亦无明显变化。治疗组行树突状细胞回输时,常见的不良反应为发热,未发现Ⅲ级以上的毒副作用。结论树突状细胞对晚期卵巢癌患者有治疗疗效,毒副反应较轻,可改善患者的生活质量。
Objective To observe the change of CA125 level in the peripheal blood in ovarian cancer before and after dendritic cell （DC ） therapy, and observe its clinical curative effect and side effect on patient with ovan＇an cancer. Methods Twenty patients with advanced ovarian cancer were randomly divided into best support care group （ the control goup ） and dendritic cell therapy group （ observation group ）. Sensitized matured DCs, derived from peripheal blood monocytes of the patients in observation group,were administered after a week. The patients in the control group received the best support care. The CA125 level was detected before and after the treatment. The toxicity of DCs and patients＇ KPS were observed. Results The CA125 level and KPS were not significant difference in the two groups before treatment. In observation group, the CA125 level significantly decreased and KPS significantly increased after treatment. There was statistical difference. The CA125 level in the control group and KPS were not significant difference. In observation group,after sensitized matured DCs were administered,fever was common side effect,serious side effect was not obversed. Conclusion The dendritic cell therapy is effective for advanced ovarian cancer. Its side effect is not serious and this treatment can improve patients＇quality of life.
出处
《潍坊医学院学报》
2009年第5期347-348,共2页
Acta Academiae Medicinae Weifang
